

Vector VRC4792 Containing the Human Anti-Middle East Respiratory Syndrome Coronavirus Spike Monoclonal Antibody CDC2-C2 Heavy Chain Gene

Catalog No. NR-52020

This reagent is the tangible property of the U.S. Government.

For research use only. Not for use in humans.

Contributor:

Barney Graham, Deputy Director and Chief, Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA

Manufacturer:

BEI Resources

Product Description:

NR-52020 is an expression vector containing a 1428 base pair (VH+CH) insert that encodes a human anti-Middle East respiratory syndrome coronavirus (MERS-CoV) spike (S) monoclonal antibody CDC2-C2 heavy chain gene. The vector contains regulatory elements CMV enhancer/promoter, CMV IE splicing acceptor and HTLV-1 R region/splicing donor. Human Ig heavy leader is provided as the targeting sequence. The kanamycin resistance gene, *aph*, provides transformant selection through kanamycin resistance in *Escherichia coli* (*E. coli*). The resulting size of the plasmid is approximately 5800 base pairs. NR-52020 is also referred to as VRC4792_CDC2-C2H.¹ The complete plasmid sequence and map are provided on the BEI Resources webpage. The plasmid was produced in *E. coli* and extracted.

The neutralizing human monoclonal antibody CDC2-C2 binding to both RBD (receptor) and subunit S1 was isolated from a laboratory-confirmed Florida/USA-2 MERS patient using MERS-CoV specific probes combined with single B cell cloning strategy.² CDC2-C2 heavy chain mRNA was reverse-transcribed and amplified by nested PCR and cloned into an expression vector containing constant region of the human Ig heavy (y) chain.²

The S glycoprotein mediates viral binding to the host dipeptidyl-peptidase 4 (DPP4). This protein forms a trimer, and when bound to a host receptor, allows fusion of the viral and cellular membranes. The S protein is a target for neutralizing antibodies.³

Material Provided:

Each vial contains plasmid DNA in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0). The DNA concentration and volume provided are shown on the Certificate of Analysis. The vial should be centrifuged prior to opening. Note: The contents of the vial should be used to replicate the plasmid in *E. coli* prior to mammalian expression.

Packaging/Storage:

NR-52020 was packaged aseptically in screw-capped plastic cryovials. The product is provided frozen on dry ice and should be stored at -20°C or colder immediately upon arrival. Freeze-thaw cycles should be minimized.

Citation:

Acknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Vector VRC4792 Containing the Human Anti-Middle East Respiratory Syndrome Coronavirus Spike Monoclonal Antibody CDC2-C2 Heavy Chain Gene, NR-52020.”

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. [Biosafety in Microbiological and Biomedical Laboratories \(BMBL](#), 6th ed. Washington, DC: U.S. Government Printing Office, 2020.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

NR-52020 is claimed in U.S. Patent No. 7,094,598 and U.S. Patent Application No. 15/553,466 and the continuations, continuations-in-part, re-issues and foreign counterparts thereof.^{4,5} NR-52020 cannot be transferred to for-profit entities.

References:

1. Graham, B., Personal Communication.
2. Wang, L., et al. "Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein to Avoid Neutralization Escape." *J. Virol.* 92 (2018): e02002-17. PubMed: 29514901.
3. Rabaan, A. A., et al. "SARS-CoV-2, SARS-CoV, and MERS-COV: A Comparative Overview." *Infez. Med.* 28 (2020): 174-184. PubMed: 32275259.
4. Graham, B., et al. "Middle East Respiratory Syndrome Coronavirus Immunogens, Antibodies, and their Use." [U.S. Patent Application 15/553466](#), 2018.
5. Nabel, G. J. and Z. Yang. "Development of a Preventive Vaccine for Filovirus Infection in Primate." [U.S. Patent No. 7094598](#), 2006.

ATCC® is a trademark of the American Type Culture Collection.

